Lavelle Erin 4
4 · Neoleukin Therapeutics, Inc. · Filed Jun 9, 2023
Insider Transaction Report
Form 4
Lavelle Erin
Director
Transactions
- Award
Stock Option (Right to Buy)
2023-06-08+25,000→ 25,000 totalExercise: $0.79Exp: 2033-06-07→ Common Stock (25,000 underlying)
Footnotes (1)
- [F1]The option vests as to 1/12 of the total shares monthly beginning July 8, 2023 until the option is fully vested on June 8, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.